¼¼°èÀÇ ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå º¸°í¼­(2025³â)
Bioconvergence Global Market Report 2025
»óǰÄÚµå : 1760482
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,222,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,993,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,765,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â¿¡´Â 11.1%ÀÇ CAGR·Î 2,435¾ï 3,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº Àç»ýÀÇ·á ÀÀ¿ë ºÐ¾ß È®´ë, ¸¸¼ºÁúȯ À¯º´·ü Áõ°¡, ¹ÙÀÌ¿ÀÀüÀÚ ¹× ¹ÙÀÌ¿À¼¾¼­ äÅà Ȯ´ë, Àΰø »ýüÀç·á °³¹ß, »ý¸í°øÇÐ ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ ±ÞÁõ¿¡ ±âÀÎÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ½Å¾à°³¹ß¿¡ ÀΰøÁö´ÉÀÇ ÅëÇÕ, ·¦¿ÂĨ ±â¼úÀÇ ¹ßÀü, ¿þ¾î·¯ºí ¹ÙÀÌ¿À¼¾¼­ÀÇ ¼ºÀå, 3D ¹ÙÀÌ¿ÀÇÁ¸°ÆÃÀÇ È°¿ë È®´ë, Ç¥ÀûÄ¡·á¿¡ ³ª³ë·Îº¿°øÇÐÀÇ È°¿ë, Àå±â¿ÂĨ ¸ðµ¨ÀÇ Ã¤ÅÃ, À¯ÀüÀÚ ÆíÁý ±â¼úÀÇ ¹ßÀü µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

°³ÀθÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀÇ ¼ºÀåÀÌ °¡¼ÓÈ­µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ÂÃãÀÇ·á´Â Ä¡·á °á°ú¸¦ ÃÖÀûÈ­Çϰí Ä¡·á¸¦ °­È­Çϱâ À§ÇØ È¯ÀÚ °³°³ÀÎÀÇ À¯ÀüÀû, ȯ°æÀû, »ýȰ½À°üÀû ¿äÀο¡ µû¶ó Ä¡·á¸¦ ¸ÂÃãÈ­ÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. À¯Àüü ±â¼úÀÇ ¹ßÀüÀ¸·Î À¯ÀüÀÚ º¯À̸¦ º¸´Ù Á¤È®ÇÏ°Ô ÆÄ¾ÇÇÒ ¼ö ÀÖ°Ô µÇ¾î °³Àκ° ¸ÂÃã Ä¡·á°¡ °¡´ÉÇØÁü¿¡ µû¶ó ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿ÀÄÁ¹öÀü½º´Â ÷´Ü ±â¼ú°ú »ý¹°ÇÐÀû ¿¬±¸¸¦ ÅëÇÕÇÏ¿© ȯÀÚÀÇ À¯ÀüÀû, ºÐÀÚÀû ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î º¸´Ù Á¤È®ÇÏ°í ¸ÂÃãÈ­µÈ Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖµµ·Ï ¸ÂÃãÇü ÀǷḦ Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀº Ç¥Àû Ä¡·á¸¦ ¿ëÀÌÇÏ°Ô ÇÏ°í ºÎÀÛ¿ëÀ» ÃÖ¼ÒÈ­ÇÏ¿© ÀÇ·á ¼º°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 2¿ù ¹Ì±¹ ºñ¿µ¸®´ÜüÀÎ °³ÀθÂÃãÀǷῬÇÕ(PMC)Àº ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ 2023³â 26°³ÀÇ ¸ÂÃãÇü ½Å¾àÀ» ½ÂÀÎÇß´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú, °³ÀθÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀå È®´ë°¡ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÄÁ¹öÀü½º ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ÀÚµ¿È­µÈ ¼ÒÇüÈ­ ´ÜÀÏ ¼¼Æ÷ ´Ü¹éÁúüÇÐ »ùÇà Á¶Á¦¿Í °°Àº Çõ½ÅÀûÀÎ Á¦Ç° °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, Á¤¹ÐÇÑ ´Ü¹éÁú ºÐ¼®À» °¡´ÉÇÏ°Ô Çϰí, »ùÇà ¼Õ½ÇÀ» ÃÖ¼ÒÈ­Çϸç, ´ÜÀÏ ¼¼Æ÷ ¿¬±¸ÀÇ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÕ´Ï´Ù. ÀÚµ¿È­µÈ ¼ÒÇüÈ­ ´ÜÀÏ ¼¼Æ÷ ´Ü¹éÁúüÇÐ »ùÇà Á¶Á¦´Â Ãʹ̷®ÀÇ °³º° ¼¼Æ÷·ÎºÎÅÍÀÇ ´Ü¹éÁú Ãë±Þ ¹× Áغñ¸¦ ÀÚµ¿È­ÇÏ´Â °úÁ¤ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù µ¶ÀÏ¿¡ º»»ç¸¦ µÐ »ý¸í°øÇÐ ±â¾÷ Scienion GmbH´Â Áú·® ºÐ¼® ±â¹Ý ´ÜÀÏ ¼¼Æ÷ ´Ü¹éÁúüÇÐ ºÐ¼®À» À§ÇÑ ÀçÇö¼º ³ôÀº ¼ÒÇüÈ­µÈ ¿öÅ©Ç÷ο츦 ÃËÁøÇÏ´Â Proteochip LF 48À» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Ã·´Ü ¹ÙÀÌ¿ÀÄÁ¹öÀü½º µµ±¸´Â °³º° ¼¼Æ÷ÀÇ ¿ÂĨ ¿ëÇØ ¹× ´Ü¹éÁú ¼ÒÈ­¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ¿¬±¸ÀÚµéÀÌ ½Ã·á ¼Õ½ÇÀ» ÁÙÀ̰í, ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϸç, È¿À²ÀûÀÎ Áú·® ºÐ¼®À» ÅëÇØ ´õ ±íÀº »ý¹°ÇÐÀû ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. Á¤È®ÇÑ ¼¼Æ÷ ó¸®¿Í ¿ÂĨ ¶óÀÌ½Ì ¹× ´Ü¹éÁú ¼ÒÈ­¸¦ °áÇÕÇÏ¿© ´Ù¾çÇÑ ´ÜÀÏ ¼¼Æ÷ ´Ü¹éÁúüÇÐ ¾ÖÇø®ÄÉÀ̼ǿ¡ È¿°úÀûÀÎ ½Ã·á Àü󸮸¦ Á¦°øÇÏ¿© ±Ã±ØÀûÀ¸·Î ¿öÅ©Ç÷οìÀÇ È¿À²¼º°ú µ¥ÀÌÅÍ Ç°ÁúÀ» Çâ»ó½Ãŵ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Bioconvergence is the integration of biology with engineering, data science, and advanced technologies to drive innovation in healthcare, biotechnology, and life sciences. The main objective of bioconvergence is to develop smarter, more personalized, and more efficient solutions such as precision medicine, advanced diagnostics, and bioengineered products. It enables the creation of faster, more cost-effective, and more impactful therapies, devices, and platforms.

The primary components of bioconvergence include devices, software, services, and platforms. Devices refer to hardware or tools that interact with biological systems, combining biology, engineering, and digital technology. This integration involves various advanced technologies such as artificial intelligence, robotics, 3D printing, nanotechnology, synthetic biology, bioinformatics, and wearable devices. These technologies support a wide range of applications, including drug discovery, regenerative medicine, optogenetics, nanorobotics for targeted therapies, diagnostic and biosensing tools, bioelectronics, and precision medicine. Key end users of these innovations include pharmaceutical and biotechnology companies, contract research organizations, and other stakeholders in the healthcare and life sciences industries.

The bioconvergence market research report is one of a series of new reports from The Business Research Company that provides bioconvergence market statistics, including bioconvergence industry global market size, regional shares, competitors with a bioconvergence market share, detailed bioconvergence market segments, market trends and opportunities, and any further data you may need to thrive in the bioconvergence industry. This bioconvergence market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioconvergence market size has grown rapidly in recent years. It will grow from $143.20 billion in 2024 to $159.66 billion in 2025 at a compound annual growth rate (CAGR) of 11.5%. The growth during the historic period can be attributed to the rise of personalized medicine, advancements in biomedical engineering, increasing healthcare digitization, the development of bioinformatics, and the collaboration between technology and biotechnology industries.

The bioconvergence market size is expected to see rapid growth in the next few years. It will grow to $243.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the expansion of regenerative medicine applications, rising prevalence of chronic diseases, increased adoption of bioelectronics and biosensors, development of engineered living materials, and a surge in investment in biotechnology research and development. Major trends include the integration of artificial intelligence in drug discovery, advancements in lab-on-a-chip technologies, the growth of wearable biosensors, the expansion of 3D bioprinting applications, the use of nanorobotics for targeted therapies, the adoption of organ-on-a-chip models, and progress in gene editing techniques.

The increasing emphasis on personalized medicine is expected to accelerate the growth of the bioconvergence market. Personalized medicine involves customizing treatments for individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and enhance care. The demand for personalized medicine is rising as genomic technologies advance, allowing for more accurate identification of genetic variations and enabling tailored treatments for individuals. Bioconvergence supports personalized medicine by integrating cutting-edge technologies with biological research, allowing for more precise, individualized treatment plans based on a patient's genetic and molecular profile. This approach improves healthcare outcomes by facilitating targeted therapies and minimizing adverse effects. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, marking a significant increase from the 12 approved in 2022. Consequently, the growing focus on personalized medicine is driving the bioconvergence market's expansion.

Leading companies in the bioconvergence market are focusing on the development of innovative products, such as automated miniaturized single-cell proteomics sample preparation, to enable precise protein analysis, minimize sample loss, and streamline workflows in single-cell research. Automated miniaturized single-cell proteomics sample preparation is a process that automates the handling and preparation of proteins from individual cells in ultra-low volumes. For instance, in September 2022, Scienion GmbH, a biotechnology company based in Germany, introduced the Proteochip LF 48, which facilitates reproducible and miniaturized workflows for mass spectrometry-based single-cell proteomics analysis. This advanced bioconvergence tool enables on-chip lysis and protein digestion of individual cells, helping researchers reduce sample loss, simplify workflows, and gain deeper biological insights through efficient mass spectrometry analysis. The Proteochip LF 48 is highly adaptable, offering effective sample preparation for a wide range of single-cell proteomics applications by combining precise cell handling with on-chip lysis and protein digestion, ultimately enhancing workflow efficiency and data quality.

In May 2022, BICO Group AB, a biotechnology company based in Sweden, acquired Allegro 3D Inc. for an undisclosed amount. This acquisition strengthens BICO's bioconvergence portfolio by integrating Allegro 3D's digital light processing (DLP) technology, which enables high-speed, precise bioprinting for regenerative medicine and drug testing, while also supporting scalable, animal-free tissue development. Allegro 3D Inc., based in the U.S., specializes in DLP bioprinting technology and contributes to bioconvergence through its high-precision tissue engineering and drug testing solutions.

Major players in the bioconvergence market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Veolia Environnement S.A, Novartis AG, Eli Lilly and Company, Amgen Inc., HDR Inc., Ginkgo Bioworks, BICO Group AB, MeMed Diagnostics Ltd., Anima Biotech, Singota Solutions LLC, SetPoint Medical Corporation, Galvani Bioelectronics, Ezassi Inc., Tissue Dynamics Ltd., Sanara Ventures Ltd., BioConvergent Health LLC, Gradiant Bioconvergence Center.

North America was the largest region in the bioconvergence market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Bioconvergence market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioconvergence market consists of revenues earned by entities by providing services such as personalized medicine development, biomedical data analysis, bioinformatics platforms, regenerative medicine solutions, diagnostic technology integration, and smart medical device engineering. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioconvergence market also includes sales of bioprinted tissues and organs, lab-on-a-chip devices, smart implants, bioengineered materials, and integrated diagnostic tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bioconvergence Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bioconvergence market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bioconvergence ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bioconvergence market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Bioconvergence Market Characteristics

3. Bioconvergence Market Trends And Strategies

4. Bioconvergence Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bioconvergence Growth Analysis And Strategic Analysis Framework

6. Bioconvergence Market Segmentation

7. Bioconvergence Market Regional And Country Analysis

8. Asia-Pacific Bioconvergence Market

9. China Bioconvergence Market

10. India Bioconvergence Market

11. Japan Bioconvergence Market

12. Australia Bioconvergence Market

13. Indonesia Bioconvergence Market

14. South Korea Bioconvergence Market

15. Western Europe Bioconvergence Market

16. UK Bioconvergence Market

17. Germany Bioconvergence Market

18. France Bioconvergence Market

19. Italy Bioconvergence Market

20. Spain Bioconvergence Market

21. Eastern Europe Bioconvergence Market

22. Russia Bioconvergence Market

23. North America Bioconvergence Market

24. USA Bioconvergence Market

25. Canada Bioconvergence Market

26. South America Bioconvergence Market

27. Brazil Bioconvergence Market

28. Middle East Bioconvergence Market

29. Africa Bioconvergence Market

30. Bioconvergence Market Competitive Landscape And Company Profiles

31. Bioconvergence Market Other Major And Innovative Companies

32. Global Bioconvergence Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bioconvergence Market

34. Recent Developments In The Bioconvergence Market

35. Bioconvergence Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â